Sibutramine can produce dose-dependent increases in blood pressure and heart rate, especially during initial treatment. However, the cardiovascular effects of the drug are related to the weight loss achieved: patients who lose 5% or more of initial body weight have a reduction in blood pressure, which correlates with the degree of weight loss. Sibutramine does not exacerbate pre-existing controlled hypertension and treatment has been shown to be safe and effective in these patients. In clinical practice, it is important to observe the recommended exclusion criteria, to monitor blood pressure and heart rate and to adhere to the withdrawal criteria. This should enable the identification of those patients for whom sibutramine is not suitable while permitting the majority of patients to gain clinical benefit from treatment.
Introduction
The Framingham study 1 showed that more than 80% of patients with hypertension have one or more additional metabolic risk factors for cardiovascular disease. Almost one-third of hypertensive patients, of both sexes, have three or more additional risk factors. These include obesity, glucose intolerance, dyslipidaemia and left ventricular hypertrophy. Coronary heart disease risk in a patient with hypertension increases with the extent of risk factor clustering. It is, therefore, important to determine the global risk of a patient with hypertension rather than to focus solely on reducing blood pressure.
Obesity is probably the most important risk factor for hypertension. Recent evidence suggests that the reverse is also true, and that patients with hypertension are at higher risk of future weight gain than subjects with normal blood pressure. Because of this, the relationship between obesity and hypertension has been described as 'a two-way street'. 2 Thus, patients with hypertension are not only at high risk of cardiovascular disease, but they are also especially prone to future weight gain. The potential benefits of weight loss are, therefore, particularly advantageous in patients with hypertension.
Effects of sibutramine on heart rate and blood pressure
Sibutramine acts centrally to increase satiety, reduce hunger and limit the post-dieting decline in energy expenditure. The drug acts by inhibiting the reuptake of serotonin and noradrenaline. This pharmacological action, involving stimulation of the sympathetic nervous system, means that cardiovascular effects are to be expected.
In patients with uncomplicated obesity, treatment with sibutramine results in a dose-dependent increase in heart rate. There is a mean overall increase of 3 -7 bpm (Abbott Laboratories, data on file). Sibutramine can also result in a slight increase in mean blood pressure, 3 especially during the initial phase of treatment. The average increase in systolic blood pressure in patients receiving sibutramine at the nonrecommended doses of 20 and 30 mg is between 2 and 4 mmHg. However, the effects on blood pressure are lower at the currently recommended doses: there is virtually no change in systolic blood pressure in patients treated with sibutramine 10 mg and the mean increase in blood pressure in patients treated with sibutramine 15 mg is around 1 mmHg.
Several long-term studies have evaluated the effect of sibutramine treatment on blood pressure. For example, Wirth and Krause reported a placebo-controlled study carried out over 48 weeks with a sibutramine dosage of 15 mg=day.
Sibutramine is not contraindicated in patients with well-controlled hypertension and several studies conducted over the dose range 10 -20 mg have shown that treatment is safe and effective in these patients ( Figure 2 ). 5 -8 Of these studies, the only one that evaluated sibutramine at a dose of 10 mg 5 reported a decrease in systolic blood pressure which was similar in both the placebo and sibutramine groups.
It is important that sibutramine treatment is combined with non-pharmacological approaches to weight loss. These approaches, in particular physical exercise, have been found to minimize potential cardiostimulatory effects of sibutramine. Figure 3 summarizes the results of a study that was carried out to evaluate the effects of physical exercise in patients treated with sibutramine. 9 In those patients who remained sedentary, there was an increase in diastolic blood pressure and heart rate (P < 0.01). In contrast, patients who underwent an aerobic exercise programme while taking sibutramine had a significant decrease in both heart rate (P < 0.02) and blood pressure (P < 0.01).
Weight loss appears to be the most important factor determining the cardiovascular effects of sibutramine. The changes in systolic blood pressure in patients receiving sibutramine (at all the doses used in clinical trials; ie 1 -30 mg) have been assessed according to weight loss categories (Figure 4) . 3 In patients who did not lose weight or who achieved less than 5% weight loss, there was a slight increase in mean blood pressure in patients taking sibutramine. However, once patients achieved >5% weight loss there was a decline in blood pressure, which correlated with the degree of weight loss, ie the decrease in blood pressure was greater in those who lost >10% weight than those who lost >5% weight.
As Figure 4 shows, the decrease in mean blood pressure in patients treated with sibutramine is less than that in subjects who achieved equivalent weight loss by diet alone, but it is important to consider the effectiveness of diet-induced weight loss. Only 22% of patients taking placebo achieved weight loss of more than 5% compared with more than 50% of those taking sibutramine. In patients with more than 10% weight loss, the difference was even more marked: 6% of placebo patients achieved this level of weight loss compared with 23% of patients taking sibutramine.
Cardiovascular side effects and safety profile of sibutramine
The STORM Study, 10 which evaluated the long-term effect of sibutramine treatment, included a sub-set of 51 patients with controlled hypertension. Thirty-one of these patients were Sibutramine and its cardiovascular profile K Narkiewicz randomized to sibutramine and 20 to placebo. There was only one withdrawal in each group. Two patients in the sibutramine-treatment group required more antihypertensive therapy and two required less; in all other patients, antihypertensive therapy remained unchanged during sibutramine treatment. Table 1 shows collated data from patients who were withdrawn from sibutramine therapy because of cardiovascular adverse events in long-term (12 months) placebo-controlled studies. There was a slight increase in the incidence of tachycardia in patients treated with sibutramine, but there was no significant difference between sibutramine and placebo in the incidence of hypertension, palpitation or vasodilatation. Importantly, the total number of adverse cardiovascular events did not differ between sibutramine and placebo groups (9.0 and 8.7%, respectively).
Although sibutramine can lead to slight increases in mean blood pressure and heart rate, it is important to recognize that treatment with sibutramine is also associated with beneficial effects on other metabolic risk factors. For example, the STORM study 10 showed that long-term treatment (2 years) with sibutramine was associated with a marked improvement in the lipid profile, with increases in HDL cholesterol and reduction in triglycerides and VLDL cholesterol.
Clinical management: precautions and withdrawal criteria
How should patients be treated with sibutramine to gain optimum benefit from the drug? The three key issues in clinical management are to observe recommended exclusion criteria (contraindications), to monitor blood pressure and heart rate, and to adhere to withdrawal criteria.
The currently recommended exclusion criteria in the Summary of Product Characteristics (SmPC) include coronary artery disease, congestive heart failure, tachycardia, peripheral arterial occlusive disease, arrhythmias and cerebrovascular disease.
Details of the recommended blood pressure and heart rate monitoring are shown in Table 2 . To avoid misleading interpretation of the effect of sibutramine on blood pressure, it is important to measure blood pressure accurately: at least two measurements should be taken on each occasion and patients should be seated for at least 5 min before the blood pressure is measured.
There are three criteria for withdrawal of sibutramine, as recommended in the SmPC:
if resting heart rate increases by 10 bpm or systolic= diastolic blood pressure increases by 10 mmHg on two consecutive visits; if blood pressure is >145=90 mmHg on two consecutive visits in patients with previously well-controlled hypertension; if there is progressive dyspnoea, chest pain or ankle oedema.
Summary
Current evidence indicates that the cardiovascular effects of sibutramine are dose-dependent. Increases in mean blood pressure and heart rate can occur but these increases are small in patients treated with the currently recommended doses of 10 or 15 mg. In patients who achieve weight loss of more than 5%, the blood pressure would be expected to fall. Sibutramine does not exacerbate pre-existing hypertension that is well controlled with antihypertensive treatment.
Withdrawal of sibutramine therapy should be considered in patients who fail to lose weight to minimize exposure of non-responders to potential increases in blood pressure and heart rate. Careful clinical use of the drug, with due attention paid to exclusion criteria, blood pressure and heart rate monitoring and withdrawal criteria, should enable identification of those patients for whom sibutramine is not suitable, while permitting the majority of patients to gain benefits from the clinically important effects of treatment with the drug. Sibutramine and its cardiovascular profile K Narkiewicz
